Antiobesity Global Market Report 2024

The antiobesity market size has grown rapidly in recent years. It will grow from $3.38 billion in 2023 to $3.76 billion in 2024 at a compound annual growth rate (CAGR) of 11.3%. The growth observed during the historical period can be attributed to several key factors, including the rising prevalence of obesity, increased awareness and education about the condition, lifestyle changes contributing to weight issues, and government initiatives aimed at addressing the obesity epidemic.

The antiobesity market size is expected to see rapid growth in the next few years. It will grow to $5.64 billion in 2028 at a compound annual growth rate (CAGR) of 10.7%. The anticipated growth in the forecast period can be attributed to market expansion and globalization. Notable trends expected during this period include increased investment in research and development, the adoption of patient-centric approaches, expanded insurance coverage, technological advancements, the integration of digital health and telemedicine, the emergence of novel drug therapies, advancements in bariatric surgery, the availability of over-the-counter (OTC) solutions, the implementation of behavioral interventions, and the rise of nutritional and weight management apps.

Obesity is a significant global public health issue, with its prevalence increasing each year. For example, a May 2022 report from the World Obesity Atlas, a UK-based organization focused on obesity, projected that by 2030, more than 1 billion individuals worldwide are expected to be affected by obesity. This alarming trend can be attributed to the growing consumption of processed and unhealthy foods, decreased physical activity levels, and a lack of awareness regarding the risks associated with obesity. Consequently, the demand for anti-obesity drugs is poised to rise in the future, driven by the urgent need to address this global health concern and support individuals in their weight management efforts. This growing demand is expected to contribute to the expansion of the anti-obesity drug market.

The key categories of anti-obesity drugs consist of peripherally acting anti-obesity medications and centrally acting anti-obesity medications. Peripherally acting anti-obesity drugs facilitate weight loss without affecting the brain or appetite. They work by inhibiting pancreatic lipase and impeding fat breakdown in the gastrointestinal tract, consequently reducing fat absorption in the intestine. These drugs are available in various forms, including prescription drugs (Rx) and over-the-counter (OTC) medications, offering both monotherapies and combination therapies to address weight management.

The anti-obesity market research report is one of a series of new reports that provides anti-obesity market statistics, including anti-obesity industry global market size, regional shares, competitors with an anti-obesity market share, detailed anti-obesity market segments, market trends and opportunities, and any further data you may need to thrive in the anti-obesity industry. This anti-obesity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The increasing geriatric population is expected to drive the growth of the anti-obesity drugs market in the future. The geriatric population encompasses older individuals, typically aged 65 and above, and obesity remains a prevalent and significant concern within this age group. Elderly individuals, especially those with diabetes, are particularly susceptible to obesity due to reduced physical activity and impaired circulation. For example, in October 2022, reports from the World Health Organization, a specialized US-based health agency, indicated that globally, one in six individuals will be 60 years or older by 2030. Furthermore, by 2050, the number of individuals in this age group is projected to double, reaching approximately 2.1 billion. Consequently, the growing geriatric population is a significant driver of the anti-obesity drugs market, as it addresses the specific needs of older individuals in managing obesity and related health issues.

Obesity is a significant global health issue driven by sedentary lifestyles and the consumption of unhealthy foods. While several anti-obesity drugs have been approved and are available in countries like the USA, European Union, Australia, and Japan to address obesity and overweight, it's important to note that these drugs may have various adverse effects on patients undergoing obesity treatment. These adverse effects can include low blood pressure, blood glucose fluctuations, incontinence, insomnia, nausea, diarrhea, and other side effects. For instance, Sibutramine and its combination drugs, sold under various brand names, were recalled in multiple countries due to various side effects, including an increased risk of heart attack in consumers. These concerns surrounding the safety and side effects of anti-obesity drugs act as a restraint on the growth of the anti-obesity drug market, as they can influence patient and healthcare provider decisions regarding treatment options.

Major companies in the anti-obesity drugs market are dedicated to innovation, with a focus on developing new products to better serve their customers. One such innovative product is Mounjaro (tirzepatide), an anti-obesity drug designed to address the needs of adults with obesity or overweight conditions, particularly those with weight-related comorbidities. For example, in October 2022, Eli Lilly and Company, a US-based pharmaceutical company, launched Mounjaro (tirzepatide), which received fast track designation approval from the Food and Drug Administration (FDA), a US-based federal agency. Mounjaro (tirzepatide) is an injectable anti-obesity drug that aims to assist individuals struggling with obesity in achieving their weight loss goals. It is indicated for use in adults with type 2 diabetes and, when combined with a diet and exercise regimen, can help improve blood sugar (glucose) control. This type of innovation demonstrates the commitment of these companies to providing effective solutions for individuals grappling with obesity and related health issues.

The pharmaceutical industry is currently experiencing a growing trend of mergers and acquisitions among companies specializing in drug development for metabolic disorders, which encompass conditions like obesity and diabetes. This strategic approach is adopted by pharmaceutical companies to bolster their drug portfolios in the field of metabolic diseases and to introduce safe and efficacious medications to the market. For example, companies like Evotec AG and Novo Nordisk have established a strategic alliance to collaborate on the discovery and development of drug molecules designed to treat metabolic disorders. These disorders include obesity, diabetes, and related health conditions. Such collaborations and partnerships represent an effort to pool resources, expertise, and innovation in the quest to bring novel and effective drugs to individuals dealing with metabolic disorders, thereby addressing a significant health challenge.

Major companies operating in the antiobesity market include F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Boehringer Ingelheim GmbH, Pfizer Inc., Merck & Co. Inc., Takeda Pharmaceutical Company Limited, Eisai Co. Ltd., Novo Nordisk A/S, Zafgen Inc., Rhythm Pharmaceuticals Inc., Zydus Cadila, Norgine B.V., Vivus Inc., Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc., Eli Lilly and Company, Amgen Inc., AstraZeneca PLC, Novartis International AG, Viking Therapeutics Inc., Structure Therapeutics Inc., Gelesis Inc., Sanofi S.A., Johnson & Johnson, F. Hoffmann-La Roche Ltd, Teva Pharmaceutical Industries Limited, Allergan Aesthetics, Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Cipla Ltd., Lupin Ltd., Torrent Pharmaceuticals Ltd., Cadila Healthcare Ltd., Intas Pharmaceuticals Ltd., Wockhardt Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Ltd.

North America was the largest region in the anti-obesity market in 2023. Middle East is expected to be the fastest-growing region in the antiobesity market. The regions covered in the antiobesity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the antiobesity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada

The anti-obesity market consists of sales of liraglutide, semaglutide, naltrexone-bupropion, and orlistat. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.